Charles Schwab
CABA icon

Charles Schwab’s Cabaletta Bio CABA Stock Holding History

Charles Schwab’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
374,886
+324,062
+638% +$1.07M ﹤0.01% 2964
2026
Q1 		$137K Hold
50,824
– – ﹤0.01% 3347
2025
Q4 		$111K Hold
50,824
– – ﹤0.01% 3393
2025
Q3 		$119K Buy
50,824
+203
+0.4% +$348 ﹤0.01% 3382
2025
Q2 		$76.9K Sell
50,621
-109,245
-68% -$170K ﹤0.01% 3424
2025
Q1 		$221K Buy
159,866
+50,606
+46% +$108K ﹤0.01% 3242
2024
Q4 		$248K Sell
109,260
-16,585
-13% -$58.2K ﹤0.01% 3293
2024
Q3 		$594K Buy
125,845
+7,518
+6% +$43.5K ﹤0.01% 3103
2024
Q2 		$885K Buy
118,327
+24,802
+27% +$304K ﹤0.01% 2983
2024
Q1 		$1.6M Sell
93,525
-2,785
-3% -$59.8K ﹤0.01% 2658
2023
Q4 		$2.19M Buy
96,310
+305
+0.3% +$5.13K ﹤0.01% 2590
2023
Q3 		$1.46M Buy
96,005
+27,456
+40% +$375K ﹤0.01% 2680
2023
Q2 		$885K Buy
68,549
+58,471
+580% +$635K ﹤0.01% 2815
2023
Q1 		$83.3K Hold
10,078
– – ﹤0.01% 3277
2022
Q4 		$93.2K Buy
+10,078
New +$36.7K ﹤0.01% 3268
2021
Q2 		– Sell
-32,390
Closed -$360K – 3428
2021
Q1 		$360K Hold
32,390
– – ﹤0.01% 3188
2020
Q4 		$405K Buy
32,390
+1,716
+6% +$22.3K ﹤0.01% 3056
2020
Q3 		$333K Sell
30,674
-1,829
-6% -$21K ﹤0.01% 2999
2020
Q2 		$363K Buy
32,503
+13,905
+75% +$106K ﹤0.01% 2962
2020
Q1 		$136K Buy
18,598
+4,700
+34% +$64.4K ﹤0.01% 3076
2019
Q4 		$195K Buy
+13,898
New +$165K ﹤0.01% 3041

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Charles Schwab's CABA Position: Q2 2026 in Review

Charles Schwab increased its Cabaletta Bio (CABA) stake by 638% in Q2 2026, buying an estimated $1.07M and bringing the position to 374,886 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2964.

Charles Schwab first reported a position in CABA in Q4 2019 and has held it in 21 quarters since. The position peaked at $2.19M in Q4 2023. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Charles Schwab held 374,886 shares of Cabaletta Bio worth $1.17M as of Q2 2026.
  • Charles Schwab bought 324,062 Cabaletta Bio shares in Q2 2026, an estimated $1.07M.
  • Cabaletta Bio made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2964 holding.
  • Charles Schwab first reported a position in Cabaletta Bio in Q4 2019 and has held it in 21 quarters since.
  • Charles Schwab's Cabaletta Bio position peaked at $2.19M in Q4 2023.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.